|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The use of a standardized Chinese herbal formula in patients with advanced lung cancer:a feasibility study显示文摘Objective: Increasing numbers of cancer patients are using Chinese herbs(CHs). However, differences among prior studies make it difficult to draw firm conclusions about the clinical usefulness of any specific CH formula. The primary objective of this study was to establish the acceptability of taking a standardized CH formula for patients with advanced lung cancer. The secondary objective was to identify any toxicities attributable to this CH formula and to measure changes in quality of life.Methods: A single-arm, prospective study of a 6-week intervention with a selected CH formula in15 patients with stage 4 nonsmall-cell lung cancer(NSCLC, Seventh American Joint Committee on Cancer TNM staging system).Results: Patients with advanced lung cancer were interested in using the CH formula. Completion(93%)and adherence(98%) levels were very high and most patients perceived the CH treatment as easy to take and were willing to take the CHs used in the study again if it was available. About half of the patients reported adverse events, all of which were mild(Grade 1 or 2) and only a small minority(8%) were potentially related to CHs. No biochemical or hematological evidence of toxicity was observed. Overall, there were improvement in quality of life, and reduced feelings of tiredness and sleepiness.Conclusion: This study provides preliminary evidence that short-term use of a carefully selected and prepared CH formula in patients with stage 4 NSCLC is acceptable and safe. | Goulnar Kasymjanova Anh-Thi Tran Victor Cohen Carmela Pepe Lama Sakr David Small Jason Scott Agulnik Robert Thomas Jagoe | 2018 | Journal of Integrative Medicine2018，16，6： | 2 |
| 2 | Evidence of a role for T-box genes in the evolution of limb morphogenesis and the specification of forelimb/hindlimb identity显示文摘 | Gibson-Brown J Agulnik S I Champman D L | 1996 | Mech Dev1996，56，12： | 1 |
| 3 | Involvement of T-box genes Tbx2-Tbx5 in vertebrate limb specification and development显示文摘 | Gibson-Brown J J Agulnik S I Silver L M | 1998 | Development1998，125，13： | 1 |
| 4 | Advances in adjuvant therapy of gastroin- testinal stromal tumors 显示文摘 | Adekola K Agulnik M | 2012 | Curr Oncol Rep2012，14，4： | 1 |
| 5 | High risk of deep vein thrombosis in patients with non-small cell lung cancer,a cohort study of 493 patients显示文摘 | Tagalakis V Levi D Agulnik JS | | 0，，08： | 1 |
| 6 | Hyperbilirubinemia guideline ad- herence in Russia illustrates universal challenges 显示文摘 | Agulnik A Ryumina II Burgos AE | 2009 | Eur J Pediatr2009，168，10： | 1 |
| 7 | An open - label, multi- center, phase II study of bevacizumab for the treatment of anglo- sarcoma and epithelioid hemangioendotheliomas 显示文摘 | Agulnik M Yarber JL Okuno SH | 2013 | Ann Oncol2013，24，1： | 1 |
| 8 | Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromato- graphy in nonsmall cell lung cancer 显示文摘 | Cohen V Agulnik J S Ang C | 2010 | Cancer2010，116，18： | 1 |
| 9 | Phase II study of lapa- tinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non ade- noid cystic carcinoma malignant tumors of the salivary glands 显示文摘 | Agulnik M Cohen EW Cohen RB | 2007 | J Clin Oncol2007，25，25： | 1 |
| 10 | The Peter Brojde Lung Cancer Centre:a model of integrative practice显示文摘 | Grossman M Agulnik I Batist G | 2012 | Curr Oncol2012，19，3： | 1 |
| 11 | New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma 显示文摘 | Agulnik M | 2012 | Cancer2012，118，6： | 1 |
| 12 | Phase II study of lap- atinib in recurrent or metastatic epidermal growth factor recep- tor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumours of the salivary glands显示文摘 | Agulnik M Cohen EWE Cohen RB | 2007 | J Clin Oncol2007，25，25： | 1 |
| 13 | Smcy transgene does not rescue spermatogenesis in sex-reversed mice显示文摘 | Agulnik AI Harrison WR Bishop CE | 2001 | Mamm Genome2001，12，2： | 1 |
| 14 | Promising new molecular targeted thera- pies in head and neck cancer显示文摘 | Dorsey K Agulnik M | 2013 | Drugs2013，73，31： | 1 |
| 15 | Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer 显示文摘 | Cohen V Agulnik J S Jarry J | 2006 | Cancer2006，107，12： | 1 |
| 16 | High risk of deep vein thrombosis in patients with non-small cell lung cancer:a cohort study of 493 patients显示文摘 | Tagalakis V Levi D Agulnik JS | 2007 | J Thorac Oncol2007，2，72： | 1 |
| 17 | Nasopharyngeal carcinoma: current man agement, future directions and dental implications 显示文摘 | Agulnik M Epstein JB | 2008 | Oral Oncol2008，44，7： | 1 |
| 18 | High risk of deep veinthrombosis in patients with non-small cell lung cancer; a cohortstudy of 493 patients显示文摘 | Tagalakis V Levi D Agulnik JS etal | 2007 | Thorac Oncol2007，2，8： | 1 |
| 19 | High risk of deep vein thrombosis in patients with non-small cell lung cancer:a cohort study of 493 patients显示文摘 | Tagalakis V Levi D Agulnik JS | 2007 | J Thorac Oncol2007，2，8： | 1 |
| 20 | Nasopharyngeal carcinoma: current management, future directions and dental implication显示文摘 | Agulnik M Epstein J B | 2008 | Oral Oncol2008，44，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员